Research and Development forms the cornerstone of our commitment to delivering high-quality healthcare solutions to patients worldwide. Our R&D efforts integrate deep scientific expertise, advanced technologies, and global regulatory capabilities to develop differentiated medicines that address evolving healthcare needs.
With seven research centers and a multidisciplinary team of over 1,400 scientists, operating across complex generics, specialty formulations, active pharmaceutical ingredients (API), and novel therapies, we are accelerating access to quality care from scientific discovery to scalable manufacturing and global commercialization.
We continue to strengthen our biosimilar research capabilities to increase access to high-quality biologic therapies across global markets.
With a strong focus on complex drug delivery systems and differentiated technologies, our R&D strategy cuts across multiple therapy areas and advanced treatment approaches.
We continue to strengthen our capabilities across key dosage forms, including:
Our research programs are designed to serve global markets, including the U.S., Europe, Canada, Australia, India, and other emerging markets. Supported by dedicated market intelligence and research teams, we systematically identify therapeutic gaps and emerging medical needs. This enables us to prioritize the development of medicinal products that address critical disease burdens worldwide.
Our sustained R&D investments are reinforcing Lupin's product pipeline and expanding global regulatory filings. Guided by a clear portfolio strategy, we are increasingly focused on complex and differentiated products, strengthening our presence across both existing and new markets.
In FY25, we received over 50 product approvals, underscoring the growing strength of our global regulatory capabilities and the continued expansion of our differentiated product portfolio.
Protecting innovation is central to our R&D ecosystem. Our Intellectual Property Management Group plays a critical role in safeguarding scientific discoveries and strengthening our portfolio of patents and product pipelines.
Through robust governance frameworks, strong pipelines in place, and with strict data protection practices, we ensure that our intellectual assets remain secure and protected from infringement.
Currently, our IP portfolio includes 450+ active patents. These patents span multiple domains, including APIs, formulations, biologics, and novel chemical entities.
Aligned with our mission to expand treatment access, we have adopted a policy of not filing or enforcing patents for medicines addressing diseases listed under the Access to Medicine Index (ATMI) in least developed and low-income countries. This approach helps remove barriers and ensures life-saving medicines reach underserved populations.
Despite significant advances in the global healthcare ecosystem, many diseases remain without effective treatment. Our New Chemical Entity (NCE) research programs are dedicated to addressing these unmet needs through the discovery and development of novel therapies.
With a strategic focus on oncology, immunology, and metabolic disorders, our teams advance high-potential molecules from early discovery through clinical development, with the aim of delivering transformative therapies that significantly improve patient outcomes.
Technology is a key enabler in accelerating research and enhancing development efficiency. We are embedding advanced data analytics and artificial intelligence across our drug discovery and development lifecycle to drive smarter decisions, shorten timelines, and unlock new scientific insights.
Lupin remains firmly committed to transparency in clinical research and responsible data sharing. We publish trial outcomes and anonymized datasets through platforms such as ClinicalTrials.gov and other recognized research registries, enabling access for researchers, regulators, healthcare professionals, and patient communities. Through this open exchange of knowledge, we support scientific advancement and contribute to improved healthcare outcomes.
Looking ahead, we continue to strengthen collaborations with global research organizations, technology partners, and healthcare institutions to drive innovation. Our successful partnerships, deep scientific expertise, and sustained investment in research enable the development of impactful treatments and complex therapies expanding access to high-quality medicines and helping shape the future of healthcare.
